RxDoctor Payments Data

John Hergenrother, MD

Nephrology · Cincinnati, OHNPI 1073557500

Payments from drug & device makers

$848in general payments, 2019–2025

Across 36 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$173
  • Calliditas Therapeutics US Inc.$125
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$97
  • Amgen$87
  • Vifor Pharma, Inc.$74
  • Otsuka America Pharmaceutical, Inc.$65
  • plus $228 from 10 others

What the payments were for

  • Food & beverage$72485%
  • Education$12515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$848 in reported general payments places this provider in the 40th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$119,228
Medicare patients
389
Services billed
1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone56$46,063
LokelmaSodium Zirconium Cyclosilicate20$24,315
VeltassaPatiromer Calcium Sorbitex20$23,983
FarxigaDapagliflozin Propanediol16$23,054
Lanthanum Carbonate13$11,805
JardianceEmpagliflozin12$11,753
SpsSodium Polystyrene Sulfon/Sorb16$11,471
Sevelamer Carbonate47$8,027
Mycophenolate Mofetil20$3,233
Nifedipine ErNifedipine55$2,615
Doxazosin Mesylate130$1,725
Valsartan35$1,602
Chlorthalidone67$1,437
Losartan Potassium135$1,142
Amlodipine Besylate177$866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$173$47,36936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 450 nephrology providers in Ohio.

Other nephrology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →